BridgeBio Pharma Inc (NASDAQ: BBIO) kicked off on Monday, down -1.11% from the previous trading day, before settling in for the closing price of $43.99. Over the past 52 weeks, BBIO has traded in a range of $21.72-$45.48.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales drop of Healthcare Sector giant was -3.04%. While this was happening, its average annual earnings per share was recorded -1.36%. With a float of $160.86 million, this company’s outstanding shares have now reached $189.83 million.
Let’s determine the extent of company efficiency that accounts for 730 employees. In terms of profitability, gross margin is 96.95%, operating margin of -547.57%, and the pretax margin is -528.55%.
BridgeBio Pharma Inc (BBIO) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of BridgeBio Pharma Inc is 15.28%, while institutional ownership is 83.87%. The most recent insider transaction that took place on Jul 02 ’25, was worth 1,709,050. In this transaction Chief Executive Officer of this company sold 40,000 shares at a rate of $42.73, taking the stock ownership to the 955,686 shares. Before that another transaction happened on Jul 01 ’25, when Company’s Chief Executive Officer sold 40,000 for $42.54, making the entire transaction worth $1,701,400. This insider now owns 975,686 shares in total.
BridgeBio Pharma Inc (BBIO) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around -1.36% per share during the next fiscal year.
BridgeBio Pharma Inc (NASDAQ: BBIO) Trading Performance Indicators
Take a look at BridgeBio Pharma Inc’s (BBIO) current performance indicators. Last quarter, stock had a quick ratio of 4.54. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 64.82.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.53, a number that is poised to hit -0.76 in the next quarter and is forecasted to reach -1.61 in one year’s time.
Technical Analysis of BridgeBio Pharma Inc (BBIO)
Looking closely at BridgeBio Pharma Inc (NASDAQ: BBIO), its last 5-days average volume was 3.18 million, which is a jump from its year-to-date volume of 3.09 million. As of the previous 9 days, the stock’s Stochastic %D was 58.30%.
During the past 100 days, BridgeBio Pharma Inc’s (BBIO) raw stochastic average was set at 88.45%, which indicates a significant increase from 66.15% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 39.20% in the past 14 days, which was lower than the 49.68% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $37.91, while its 200-day Moving Average is $31.81. However, in the short run, BridgeBio Pharma Inc’s stock first resistance to watch stands at $43.86. Second resistance stands at $44.23. The third major resistance level sits at $44.68. If the price goes on to break the first support level at $43.04, it is likely to go to the next support level at $42.59. Now, if the price goes above the second support level, the third support stands at $42.22.
BridgeBio Pharma Inc (NASDAQ: BBIO) Key Stats
The company with the Market Capitalisation of 8.26 billion has total of 189,881K Shares Outstanding. Its annual sales at the moment are 221,900 K in contrast with the sum of -535,760 K annual income. Company’s last quarter sales were recorded 116,630 K and last quarter income was -167,420 K.
